"RECOMMENDS" · 총 23건
필터 보기현재 지수
50.3
0 = 부정 우세
50 = 중립
100 = 긍정 우세
최근 7일 기준 87,126건을 분석한 결과, 뉴스 심리지수는 50.2(균형)입니다. 긍정 4,284건(4.9%)·중립 80,703건(92.6%)·부정 2,139건(2.5%)이며, 중립 비중이 뚜렷하게 높습니다. 성향 지수는 종합 14.9(중도 균형)입니다.
TOKYO (Kyodo) -- A UNESCO advisory body has recommended adding a group of ancient sites in Nara Prefecture that show the formation of Japan's centrali
Rest of World recommends eight books that cover the history of resistance to tech, our relationship with AI companions, the danger of our dependence on Taiwan chips, and more.
Lord John Mann’s review recommends that NHS staff receive mandatory antisemitism training and bans pro-Palestinian badges to ensure Jewish patients and staff feel safe.
Anti-Semitism review recommends that badges proclaiming political support should not be worn by public health workers
As geopolitical headwinds make it tougher for equity investors to make money, Dalal Street’s top voice Nilesh Shah, managing director of Kotak Mahindra Asset Management, told a gathering of HNI investors at the ET Alpha Wealth Summit on Thursday that there are four specific investment structures which deserve a place in most portfolios right now.Shah’s first recommendation was the Special Investment Fund, or SIF, a structure that marks a meaningful shift in what is available to Indian investors. Shah noted that the mutual fund industry has, until now, been a long-only business but the SIF changes that. These are long-short, absolute return-oriented funds, designed to generate returns regardless of market direction rather than simply riding the equity tide.The second vehicle Shah flagged is performing credit AIFs. His reasoning was grounded in a simple supply-demand observation that for corporate settlements today, capital is not available from banks, mutual funds, or insurance companies.As institutional lenders have stepped back, borrowers are plenty and lenders very few. Amid this imbalance, Shah said the need is real and returns are attractive. Performing credit AIFs, which lend into this gap, are positioned to benefit directly from the scarcity of competing capital.https://youtube.com/shorts/Xa4AcXFg8hA?feature=shareThe third idea was REITs, and here Shah introduced a timing element. Over the last three years, REITs have delivered index-level returns of around 13.5%. But with interest rates rising, he suggested that the next six to nine months may present an opportunity to enter at better prices. Rising rates typically compress REIT valuations in the near term, and Shah framed any such correction as a potential entry point rather than a risk to avoid. Beyond the return potential, he positioned REITs as a portfolio diversification tool as the asset class behaves differently from equities and fixed income, and that is still underrepresented in most Indian investor portfolios.The fourth recommendation addressed global diversification but came with an important caveat. Mutual fund industry limits for overseas investment are currently full, which means the conventional route for Indian investors to access global markets through domestic mutual funds is closed. Shah pointed to Gift City as the workaround. Structures domiciled there allow investment under the Liberalised Remittance Scheme, and in his view, these Gift City-based LRS products are the practical path for investors who want global exposure while the mutual fund window remains shut.Across all four — the SIF, performing credit AIFs, REITs, and Gift City products — Shah's underlying argument was the same: in a volatile period, the portfolio needs instruments that can generate positive returns through means other than a rising equity market.(Disclaimer: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
Document calls for reform of KSEB, KSRTC and KWA, recommends merger of Kerala State Beverages Corporation and Kerala State Civil Supplies Corporation (Supplyco)
The recommendation is one of several from Lord Mann, whose review examined antisemitism within the organisation.
The Supreme Court collegium, led by Chief Justice of India Surya Kant, has recommended ten advocates and judicial officers for appointment as judges to the High Courts of Karnataka, Himachal Pradesh, and Madhya Pradesh. The recommendations include six advocates for the Karnataka HC, three judicial officers for the Himachal Pradesh HC, and one advocate for the Madhya Pradesh HC.
The Ebola outbreak raging in central Africa had a “big head-start”, the World Health Organisation (WHO) chief acknowledged Wednesday, but insisted efforts to rein in the deadly virus were making progress. The outbreak, which was declared on May 15 in the northeastern Democratic Republic of Congo (DRC), has so far been confirmed to have infected 359 people, including 61 who have died. But the actual numbers could be far higher, with the virus believed to have been spreading under the radar for some time before it was detected. “The outbreak had a big head-start and we’re still behind,” WHO chief Tedros Adhanom Ghebreyesus told reporters at the UN health agency’s headquarters in Geneva, but insisted that “we’re catching up”. Tedros, who had just returned from a trip to DRC, where he travelled to the outbreak’s epicentre in Ituri province, said he had been “very encouraged by the level of commitment I saw everywhere I went”. But challenges remain, he said, warning that “the virus is ahead of us… we need to move faster”. It has been clear from the start that the difficulties would be daunting, with the outbreak concentrated in Ituri, where decades of armed conflicts have forced millions of people from their homes and into crowded camps. Ebola patient visited UAE The region’s insecurity, limited testing capacity, lagging contact tracing and mistrust among some of the population are among the challenges facing the response, Tedros said. On top of that, no vaccine or approved treatment exists for Bundibugyo, the rare strain of Ebola behind the current outbreak. Ebola, which is passed on through close contact and bodily fluids, has killed more than 15,000 people in Africa over the past 50 years. The current outbreak — the 17th to hit the DRC — has to date seen 344 confirmed Ebola cases across three of the country’s provinces, including 60 deaths, said the WHO. The UN health agency also tallied 116 suspected cases of the disease. Fifteen cases, including one death, have also been reported in neighbouring Uganda, including a Congolese resident who had arrived there after first travelling to the United Arab Emirates, Tedros said. “WHO is working with public health authorities in Uganda and the UAE to gather additional information, assess the risk of exposure during travel, and to facilitate contact tracing,” he said. Speed up contact tracing The agency has said the risk from the outbreak is “very high” at the national level, “high” at the regional level, and “low” at the global level. Tedros stressed on Wednesday that while the WHO recommends exit screening at airports, ports and border crossings in affected countries to prevent the spread of the virus, broader limits were unhelpful. “Blanket travel restrictions imposed by some countries are disrupting supply chains and hindering the response,” he warned. “We ask countries that have imposed blanket travel restrictions to lift them.” Reining in the outbreak would instead centre on significantly bolstering and speeding up the response on the ground, including by decentralising laboratory testing in Ebola hotspots, Tedros said. At present, only around 45 per cent of known contacts of Ebola cases have been followed up, the WHO chief said. “To get ahead of the outbreak, we need to get that number up to above 90pc.” Abdi Rahman Mahamud, the WHO’s emergency alert and response director, told reporters that so far, more than 1,400 tests had been conducted. But decentralisation across five priority locations – Mongbwalu, Beni, Aru, Nyakunde and Tchomia – should soon make it possible “to do 1,000 tests a day”.
Canada and Mexico on Tuesday called for a 16-year renewal of the North American free trade agreement with the United States, in hopes of binding the three countries to a pact that US President Donald Trump has openly questioned. The agreement is vital for Canada and Mexico, as the US is their main trading partner and the destination for 75 and 80 per cent of their exports, respectively. In a letter Monday, Ottawa’s minister in charge of Canada-US trade Dominic LeBlanc said: “Canada recommends...
The CRRI team studies roads being laid in various LPS zones earmarked for returnable plots to capital-region farmers
Mumbai: Information technology stocks surged on Monday, dodging a weak broader market, with the Nifty IT index closing at its highest level since April 23, as attractive valuations and recent AI-led partnerships drew investor interest and prompted traders to build some fresh long positions.The Nifty IT index advanced 2.7%, its strongest single-day gain in nearly two weeks (since May 19), even as the benchmark Nifty declined 0.7%. Tech Mahindra, Infosys and LTM rose 3.7% each, while Persistent Systems gained 3.6%. Coforge and Oracle Financial Services Software advanced 2.6% and 2.1%, respectively."Indian IT firms are following suit of American companies like Anthropic and OpenAI by taking up contracts and tie-ups which are perceived as promising by investors," said Gaurav Sharma, head of Research, Globe Capital.Wipro's expanded Agentic AI partnership with ServiceNow and Coforge's acquisition of Encora have helped ease concerns that had weighed on the sector earlier due to AI-linked disruption fears.The rebound comes after a sharp underperformance this year. The Nifty IT index has fallen over 21% so far in 2026, compared with a 10.5% decline in the benchmark Nifty. The recent momentum has turned positive, with the IT index gaining about 3% over the past week, while the Nifty has fallen 2.7%.131452365"The open interest has doubled in the past couple of months in large-cap IT stocks, indicating a huge build-up of short positions," said Jay Vora, Technical Analyst, Mirae Asset Sharekhan. "On Monday, while short positions remained as is, traders built fresh long positions in the space."Vora said that a more meaningful short covering rally would require stocks to move above key technical levels, with most large-cap names currently 2-3% below their 40-day exponential moving averages."There are short positions in the midcap IT companies as well, but it is not as significant as the large caps," he said.The rebound in IT shares is also on account of valuations falling below 10-year averages following the recent sell-off."Large-cap names like TCS and Infosys are trading at mouthwatering levels, close to 16-17 times Price to Earnings, while midcap companies like Coforge, Oracle and Mphasis are around 20-30 times PE, which are attractive," Sharma said.While near-term volatility may persist, valuations remain compelling over a two-to-three-year horizon, he said. Sharma's top picks are OFSS, Tech Mahindra, Coforge and Mphasis, and recommends IT Exchange Traded Funds for retail investors.The momentum favours IT stocks now, though the index is nearing key hurdles."Technically, the Nifty IT index has immediate support established at the 29,300-28,900 zone, while initial resistance is positioned at 30,500, with a broader multi-week position of 31,200," said Nischal Jain, Quant Researcher, Share.Market by PhonePe.Sharma said the Nifty IT index is on the verge of a breakout from an inverse head and shoulder pattern, which could extend the rally towards 31,500.
Updating shots to better match circulating variants can improve protection as the virus changes.
Countries: Democratic Republic of the Congo, Uganda Source: World Health Organization In response to the current outbreak of Ebola disease caused by Bundibugyo virus occurring in the Democratic Republic of the Congo, with cases also reported in Uganda, WHO convened several of its expert and advisory groups. These groups assessed potential vaccines and therapeutics for both prevention and treatment of Bundibugyo virus disease (BVD). The WHO advisory groups recommended that all the products identified and considered be used exclusively within clinical trials to generate robust data and ensure safe, ethical, and effective research. WHO convened a series of meetings with the WHO R&D Blueprint technical advisory groups on candidate vaccines and therapeutics for BVD. In parallel, WHO also convened the Strategic Advisory Group of Experts on Immunization (SAGE) and its Ebola vaccine working group to advise on the potential role of licensed Ebola vaccines during BVD outbreaks. Key recommendations There are currently no licensed therapeutics or vaccines specifically approved for the prevention and treatment of BVD. Nevertheless, WHO advisory groups considered several candidate products that are promising enough to warrant prioritization for evaluation in clinical trials. WHO is now working closely with the governments of the Democratic Republic of the Congo and Uganda to facilitate the implementation of research evaluation of these products. For treatment of cases: For treatment, the independent experts recommended prioritizing three candidate therapeutics for evaluation in research (i.e. clinical trials) among confirmed BVD cases: the monoclonal antibodies MBP134 and Maftivimab®, as well as the antiviral remdesivir. Combination therapy using a monoclonal antibody and remdesivir is also recommended for evaluation. For prevention of cases: For post-exposure prophylaxis among contacts of confirmed and probable cases, the oral antiviral obeldesivir was determined to be a priority candidate, although experts noted that this approach depends on effective contact tracing, which remains operationally challenging in some of the affected areas of the Democratic Republic of the Congo. Research on post-exposure prophylaxis involves giving tablets of obeldesivir to contacts of cases to evaluate whether this prevents them from developing Ebola disease. The most promising candidate vaccine was determined by the experts to be the single-dose rVSV Bundibugyo vaccine (being developed by the International AIDS Vaccine Initiative or IAVI). The development of this single-dose vaccine candidate will likely require 7–9 months before it is ready to be assessed through a clinical trial for its ability to prevent BDV. Another candidate vaccine, ChAdOx1 Bundibugyo (being developed by Oxford University/Serum Institute of India) could potentially become available within 2–3 months for efficacy assessment through a clinical trial. However, additional animal data are still required to support and confirm further prioritization. Experts noted that a single-dose vaccine approach of this candidate could be suitable for contacts of Ebola cases, whereas a two-dose strategy might be considered for high-risk but unexposed populations such as health-care workers and frontline responders. The convened experts also reviewed the potential role of Ervebo, the only licensed Ebola vaccine. It is approved for use during outbreaks caused by the most common Ebola virus in Africa, from the Orthoebolavirus family. Ervebo is not licensed for prevention of BVD and evidence on cross-protection to other Ebola virus species remains limited and inconclusive. WHO recommends that Ervebo should not be used outside carefully designed research settings, to allow for its performance against BDV to be assessed. Ensuring ethical and safe clinical trials WHO, the governments of the Democratic Republic of the Congo and Uganda, the Africa Centres for Disease Control and Prevention (Africa CDC), the ANRS Emerging infectious diseases (French National Agency for Research on AIDS and Viral Hepatitis), and other scientific partners are working together to develop and implement appropriate protocols to assess the safety and efficacy of the prioritized therapeutics through clinical field trials. WHO calls for accelerated access to essential supplies, stronger community protection, engagement and trust, and coordinated investment in the research, development and evaluation of BVD countermeasures. All research must adhere to the highest ethical standards, under the leadership of the national health authorities and in close consultation with affected communities. In the meantime, our priority is to stop transmission with tools that we have used for decades of Ebola responses, which include disease surveillance, rapid testing and diagnosis, contact tracing, isolation and care for patients, infection prevention and control, community engagement, and safe and dignified burials. Background The WHO R&D Blueprint is a global initiative that allows the rapid activation of research and development activities during epidemics. Its aim is to fast-track the availability of proven effective tests, vaccines, and medicines that can be used to save lives and avert large-scale crises. SAGE is the principal advisory group to WHO for vaccines and immunization. It is charged with advising WHO on overall global policies and strategies, ranging from vaccines and technology, research and development, to delivery of immunization and its linkages with other health interventions. Media Contacts WHO Media Team World Health Organization Email: mediainquiries@who.int
A Food and Drug Administration advisory panel on Thursday recommended updating this fall’s Covid shots to target the XFG variant, a fast-growing strain nicknamed “stratus.”The recommendation — from the FDA’s Vaccines and Related Biological Products Advisory Committee — is meant to help vaccine makers prepare shots for the fall and winter, when Covid infections typically rise
The recommendations will now be forwarded to the Union government for approval and issuance of warrants of appointment by the President.
MANILA, Philippines — The Philippine National Police Firearms and Explosives Office (PNP FEO) has recommended the cancellation of Sen. Ronald “Bato” dela Rosa’s firearms licenses. “As early as last week, the FEO already conducted the motu propio investigation or inquiry. We did not wait for the NBI’s (National Bureau of Investigation) request for the cancellation,”
Dr. Milica McDowell says the 10,000 steps per day benchmark is a 'marketing myth' and recommends a different range.
MANILA, Philippines — The Criminal Investigation and Detection Group (CIDG) has recommended the filing of charges against suspended Senate Sergeant-at-Arms Mao Aplasca and two of his personnel over the shooting that created chaos inside the Senate last week. In a press briefing at Camp Crame on Wednesday, CIDG director Maj. Gen. Robert Alexander Morico II maintained
The incumbent Registrar General of the High Court S. Alli is among those whose names have been recommended for elevation